

(Tel: 400-999-8863 ■ Email:Upingbio.163.com





JAK3 (Phospho-Tyr904) rabbit pAb

Catalog No YP-Ab-10549 Isotype IgG Reactivity Human; Mouse;Rat Applications WB Gene Name JAK3 Protein Name JAK3 (Phospho-Tyr904) Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse,Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein - Cytoplasm . Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonyl seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.		
Reactivity Human; Mouse;Rat Applications WB Gene Name JAK3 Protein Name JAK3 (Phospho-Tyr904) Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse;Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dillution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein . Cytoplasm . Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoleic lines, whereas the B-form is detected in cells both of hematopoleic and epithelial origins. Function catalytic activity: ATP + a [protein]-L-tyrosine phosphate, disease: Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/IK-cell-Inegative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characteristic of all types of SCID is absence of T-cell-mediated cellular immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infracy with recurrent, persistent infections of popportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development, domain: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of one probably contains the catalytic domain (By similarity) while the presence of one probably contains the catalytic domain (By similarity), while the pres	Catalog No	YP-Ab-10549
Applications Gene Name JAK3 Protein Name JAK3 (Phospho-Tyr904) Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein . Cytoplasm . Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function Catalytic activity-ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease: Defects in JAK3 are a cause of severe combination municodeficiency autosomal recessive T-cell-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/B-cell-positive/Brx-6el-negative/Brx-6el-positive/Brx-6el-negative/Brx-6el-positive/Brx-	Isotype	IgG
Gene Name JAK3 (Phospho-Tyr904) Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit.lgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein . Cytoplasm . Tinsue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negiative (T-c)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development, domain. Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Reactivity	Human; Mouse;Rat
Protein Name JAK3 (Phospho-Tyr904) Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Endomembrane system; Peripheral membrane protein . Cytoplasm . Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity.ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. disease. Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive Treell-regative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MiM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disord	Applications	WB
Immunogen Synthesized peptide derived from human JAK3 (Phospho-Tyr904) Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse,Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive received by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infrancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID	Gene Name	JAK3
Specificity This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit, IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (TC-)B(+)NK(-)SCID) [MM:60802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-nediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell absence of T-cell development, domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By smillatirty), while the presence of	Protein Name	JAK3 (Phospho-Tyr904)
Formulation Liquid in PBS containing 50% glycerol, and 0.205% sodium azide. Source Polyclonal, Rabbit,IgG Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. disease:Defects in JAK3 are a cause of severe combined immunodefficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development, domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domains the restablytic domains.	Immunogen	Synthesized peptide derived from human JAK3 (Phospho-Tyr904)
Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate., disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MiM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impariment of both humoral and cell-mediated minunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development., domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Specificity	This antibody detects endogenous levels of JAK3 (Phospho-Tyr904) at Human, Mouse,Rat
Purification The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/BK-cell-positive/NK-cell-lengative/HK-cell-lengative/HK-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development, domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Formulation	Liquid in PBS containing 50% glycerol, and 0.205% sodium azide.
using specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein . Cytoplasm . Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphatedisease:Defects in JAK3 are a cause of severe combined immunodefficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell developmentdomain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Source	Polyclonal, Rabbit,IgG
Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persisterions by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development, domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Purification	
Purity ≥90% Storage Stability -20°C/1 year Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate., disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development., domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Dilution	WB 1:500-2000
Synonyms Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Concentration	1 mg/ml
Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) Observed Band Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate, disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Purity	≥90%
Janus kinase (L-JAK)	Storage Stability	-20°C/1 year
Cell Pathway Endomembrane system; Peripheral membrane protein. Cytoplasm. In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Synonyms	
Tissue Specificity In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Function catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Observed Band	
The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Cell Pathway	Endomembrane system ; Peripheral membrane protein . Cytoplasm .
phosphate.,disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.,domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of	Tissue Specificity	The S-form is more commonly seen in hematopoietic lines, whereas the B-form is
	Function	phosphate., disease: Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development., domain: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of



UpingBio technology Co.,Ltd

📞 Tel: 400-999-8863 🗷 Emall:Upingbio.163.com



Background	The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease). [provided by RefSeq, Jul 2008],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images



Western Blot analysis of various, using primary antibody at 1:1000 dilution. Secondary antibody(catalog#:RS23920) was diluted at 1:10000